As of Feb 23, 2025, BeiGene, Ltd.'s P/E ratio is (2.1x). This is calculated by dividing the current share price of N/A by the Earnings per Share (EPS) for the trailing twelve months, which is N/A. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

Is BeiGene, Ltd. overvalued or undervalued?

BeiGene, Ltd. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $2,805.9, compared to a market price of around $226.7. This suggests a potential undervaluation of 1,137.7%.